Led by Fredrik Debong, bringing operator know-how and deep networks to the table via his successful ventures in diabetes care, fintech, and innovation management.
As a serial entrepreneur and angel investor, his work has impacted millions, and Nineteen Twenty-One is leveraging this experience to invest in and support companies realising life changing solutions in areas related to type 1 diabetes.
Simple.
Make type 1 diabetes and all it carries with it suck less.
How hard can it be!? :P
Invest in life changing early stage companies,
making them part of the T1D-community,
and the community part of the companies.
Be the smartest money in T1D.
Work together.
Invest early, fast and globally.
Be lean and transparent.
No squeezing, be a bud.
You help, you get.
This is a we-thing.
One does not do diabetes alone. One does not help companies on ones own. Our approach to taking on diabetes care challenges, and delivering a return to limited partners, is by working with/in a global network of industry professionals, clinicians, patients, researchers, policymakers, angels, savants, GP's of huge VC funds, bankers, grass root advocates and leaders of global policy organisations. Most of us live with T1D.
And many more <3
We'd be honoured to speak with you, thanks for focusing on our area of passion, experience and knowledge!
There are a few things to keep in mind, on both our ends, that we hope you understand and mind:
– We invest in companies addressing type 1 diabetes and the stuff that kills us
– It is your company, we are here to help you grow it like crazy
– We buy our way into being able to help you make decisions
– Some stuff is simply waaay out there, we like that
– We do first money in, up to select series A's
– The fund is not huge, our goal is €10M
– We have not yet raised the whole fund, work in progress
– We invest €200k-1.5M, depending on stage
– We do our first checks in companies during 2025-2028, then only follow on
– We must invest 70% of our capital in EU
– Time is short, an intro through shared friends helps.
Here’s where we stand.
We’re in Year 2 of operations, started December 2024.
We deploy initial investments for the next ~3 years.
We back mission-driven teams building tech-enabled or biology-driven solutions, fast and without excuses. We offer direct access into the core of science and tech in T1D, and can smell BS from long ways off.
We’re actively raising and deploying. That means available capital changes month to month.
If you’re curious, just ask, we’re transparent.
FMI/Pre-Seed: Lead with €250k
Seed: We prefer lead with €500K
Pre-A: €250–750K
Series A: We follow with €500K–1.5M
We will seldom lead, so count on 1/3 of the above sums if we follow.
It changes, so not smart to put on a webpage, best to ask directly.
As of October 2026 we have now done 9 investments in 8 companies. 2 FMI, 2 pre-seed, 4 seed, 1 pre A (followed in all but 2).
We’ve allocated 20% of the fund for follow-ons. We will rather offer our LP's or friends to come in to invest in SPV's to hold our pro rata if we have to.
MOIC of 6x on the fund. Right now on a good path there.
Average for VC is ~2.3x in EU. I know! Crazy… Freds angel portfolio is around 6x, and in diabetes >10x… so kinda hope to replicate that for my investors here in 1921.
It’s still early, so TVPI and DPI metrics will matter more from year 5 onward.
Two. We keep board seats focused so we can actually contribute, not just repeat blogpost'y wisdom and ask for more traction.
Depends on fund stage, allocation, and check size.
The best way to know? Ask. We’ll give you a straight answer.
If we love what you’re doing, maybe.
If we set up an SPV, we reserve the right to roll it into our next fund.
Possibly! But let’s meet first. If the chemistry’s right and there’s trust, we love making LPs proud of the founders we back. ❤️
Both! We’re actively raising capital and actively deploying it—into the founders and companies we believe in.
Let’s talk →
If you find this specialist fund focused on T1D looks good, let's meet up.
Before we can go really deep, we also need to make sure that we CAN work together. See we can only manage capital for accredited, risk aware and sophisticated investors. It's the law.
Investing in making diabetes suck less
1921.vc
Contact/socials
© 2024 Fredrik Debong
Imprint: Nineteen Twenty GmbH | FN 649344 v; Commercial court: Vienna Commercial Court, Austria
Contact:
Nineteen Twenty GmbH | 649344v
1921 Fund I: 1921 I EuVECA GmbH & Co. KG | 644756x
Wasagasse 11 / 9
1090 Vienna
Austria
Court of Jurisdiction: Vienna Commercial Court
Email: fred@1921.vc
Phone: +4369911033609
Website: 1921.vc
Basics
Information according to Article 14 Corporate Code (Unternehmensgesetzbuch), Article5 Para. 1 E-Commerce Act (E-Commerce-Gesetz) and disclosure according to Article 25 Media Act (Mediengesetz). This website is operated by Nineteen Twenty GmbH, Wasagasse 11/13, 1090 Vienna, Austria and is designed to provide information about the company, investment funds, securities, capital markets and investments.
The content of this website is solely for informational purposes and may not be construed as legal, tax, investment, financial, or other advice. Nothing contained on this website constitutes a solicitation, recommendation, endorsement, or offer(or an invitation to offer) to buy or sell any shares or other rights in any listed alternative investment fund. While every effort has been made to ensure the accuracy, topicality and completeness of the content of this website, to the extent legally permissible, no guarantee is given and neither Nineteen twenty GmbH nor any of its affiliates can be held liable for any information contained herein. In particular, the content hereof is subject to further assessment and updating.
Management of 1921 I EuVECA GmbH & Co. KG
Infra One AT Management GmbH, previously Allocator One Management GmbH, is licensed as an Alternative Investment Fund Manager pursuant to §§ 4 (1) and 6 (1) Austrian Alternative Investment Fund Managers Act (AIFMG) and registered as EuVECA Fund Manager pursuant to Regulation (EU) No 345/2013 on European Venture Capital Funds.
Managing Directors
Veronika Lang, Michael Ströck
Supervisory authority in Austria:
Financial Market Authority (FMA)
Securities Supervision
Otto-Wagner-Platz 5A
1090 Vienna
Website: www.fma.gv.at
Privacy Policy
At 1921.vc, we take your privacy seriously. We do not use cookies or tracking technologies on our website. Any personal data you provide (e.g., through contact forms) will be handled in compliance with the General Data Protection Regulation (GDPR).
We collect and process:
- Name and contact details (if you submit them via forms).
- Email addresses for communication purposes.
Your data will not be shared with third parties unless required by law. You have the right to request access, correction, or deletion of your data at any time by contacting us at fred@1921.vc.
Terms of Service
Welcome to 1921.vc. By using our website, you agree to the following terms:
- The content provided on this site is for informational purposes only and does not constitute financial or investment advice.
- You may not copy, reproduce, or distribute any content from this site without permission.
- We reserve the right to modify these terms at any time.
For any questions regarding the use of this website, please contact us at fred@1921.vc
Third Party Tools
We use pagy.co to build and maintain our super simple website. Built by this guy Manny and he seems a nice chap ;) Oh and as no sensitive information is requested by us we are fine with this service built by one guy simply not stating much about how they handle things, and will assume you are too. We're in touch to help him rectify this, but give the guy a break, for now.
For further details, please reach out to our Data Protection Officer, fred@1921.vc.
Cookie Disclaimer
We… don't use cookies. We simply are not good at baking, or see the need of them on this site.
But if you REALLY want a disclaimer, please write one on a postit and slap it on your screen :)
Disclaimer
1921 VC is an EUVECA-registered venture capital fund operating under the European Venture Capital Fund (EUVECA) Regulation (EU) No. 345/2013. The information provided on this website is intended exclusively for professional investors as defined under Directive 2014/65/EU (MiFID II) and other eligible investors who meet the requirements of the EUVECA framework.
No Public Offering
The content on this website does not constitute an offer to sell or a solicitation to invest in any jurisdiction where such an offer or solicitation would be unlawful. This website is provided for informational purposes only and should not be construed as investment, legal, or tax advice.
Investor Eligibility
Investment opportunities offered by 1921 VC are not open to the general public and are restricted to:
✅ Professional investors, including institutional investors, family offices, and asset managers
✅ High-net-worth individuals (HNWIs) who commit a minimum of €100,000 and acknowledge the associated risks
✅ Other eligible investors as defined by the EuVECA regulation
Risk Warning
Investing in venture capital involves a high degree of risk, including the risk of total loss of capital. Past performance is not indicative of future results. Prospective investors should consult their own financial, legal, and tax advisors before making an investment decision.
By visiting this page, you confirm that:
✅ You are a professional investor or an eligible investor under EUVECA rules
✅ You understand the risks associated with venture capital investments
✅ You acknowledge that this website does not constitute an investment offer
OR
✅ You were asked for feedback on the page!